Sector News

Celgene Corporation Announces the Appointment of Gerald F. Masoudi as Executive Vice President, General Counsel and Corporate Secretary

April 2, 2015
Life sciences
Celgene Corporation (CELG) today announced the appointment of Gerald F. Masoudi as Executive Vice President, General Counsel and Corporate Secretary, effective June 1, 2015. Mr. Masoudi will be responsible for global legal strategy and will serve on the company’s Executive Committee.
 
Mr. Masoudi will succeed Lawrence V. Stein, Celgene’s Executive Vice President, General Counsel and Corporate Secretary since 2012, who is retiring from Celgene following a distinguished business and legal career that also included serving as General Counsel for Wyeth and Genetics Institute and as a partner at the law firm Arnold & Porter.
 
“Larry Stein has served as a valued member of Celgene’s senior leadership team and provided the company important strategic legal counsel,” said Robert J. Hugin, Chairman and CEO of Celgene Corporation. “Celgene is deeply grateful for Larry’s significant contributions during his tenure as General Counsel.”
 
“Jerry brings a wealth of experience to Celgene” said Mr. Hugin. “His deep understanding of regulatory policy and his significant healthcare-related legal expertise will add valuable perspective to our leadership team.”
 
Mr. Masoudi joins Celgene from Covington & Burling LLP, a leading international law firm, where he is a partner and serves as co-chair of the Food and Drug practice group. At Covington, he has advised multinational companies and trade associations on significant litigation, enforcement, regulatory and public policy matters. Before joining Covington, Mr. Masoudi served as Chief Counsel of the U.S. Food and Drug Administration. Before joining FDA, Mr. Masoudi served as Deputy Assistant Attorney General for international, policy and appellate matters in the Antitrust Division of the U.S. Department of Justice. Before his government service, Mr. Masoudi was a trial and litigation partner with the law firm Kirkland & Ellis. Immediately following his graduation from law school, he clerked for Judge Frank H. Easterbrook of the U.S. Court of Appeals for the Seventh Circuit.
 
Mr. Masoudi received his J.D. from The University of Chicago Law School, graduating with high honors and serving on the editorial board of the Law Review. He received his B.A. in economics from Amherst College, Phi Beta Kappa.
 
Source: Celgene

comments closed

Related News

June 24, 2022

Echosens and Novo Nordisk announce partnership to increase awareness and advance early diagnosis of NASH

Life sciences

Echosens, a high-technology company offering liver diagnostic solutions, and Novo Nordisk A/S, a leading global healthcare company, announced a partnership to advance early diagnosis of non-alcoholic steatohepatitis (NASH) and increase awareness of the disease among patients, healthcare providers and other stakeholders.

June 24, 2022

argenx receives positive CHMP opinion for Efgartigimod for the treatment of adult patients with Generalized Myasthenia Gravis in Europe

Life sciences

Positive opinion based on Phase 3 ADAPT trial showing efgartigimod provided clinically meaningful improvements in strength and quality of life measures. If approved, efgartigimod will be the first neonatal Fc receptor (FcRn) blocker for the treatment of adults in Europe living with rare neuromuscular disease generalized myasthenia gravis (gMG).

June 24, 2022

Galapagos finally takes M&A plunge, spending $251M for 2 biotechs in CAR-T push

Life sciences

Galapagos CEO Paul Stoffels, M.D., has finally taken the plunge on M&A. The newly minted chief executive has signed not one but two deals in an attempt to right the ship, bringing two small biotechs aboard for a combined 239 million euros ($251.4 million).